Current Report Filing (8-k)
October 31 2017 - 4:25PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
October 27, 2017
Enumeral
Biomedical Holdings, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-55415
|
99-0376434
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer
Identification Number)
|
200
CambridgePark Drive, Suite 2000
Cambridge,
Massachusetts
(Address
of Principal Executive Offices)
|
|
02140
(Zip
Code)
|
(617)
945-9146
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
|
|
On
October 27, 2017, Allan Rothstein resigned from the Board of Directors of Enumeral Biomedical Holdings, Inc. (the “Company”).
Mr. Rothstein’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s
operations, policies or practices.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ENUMERAL BIOMEDICAL HOLDINGS,
INC.
|
|
|
Dated:
October 31, 2017
|
By:
|
/s/
Kevin G. Sarney
|
|
|
Name:
Kevin G. Sarney
Title: Interim
Chief Executive Officer and President, Vice President of Finance, Chief Accounting Officer and Treasurer
|